S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
NASDAQ:VYGR

Voyager Therapeutics (VYGR) Stock Price, News & Analysis

$9.31
-0.25 (-2.62%)
(As of 03/28/2024 ET)
Today's Range
$9.20
$9.68
50-Day Range
$7.15
$10.35
52-Week Range
$6.06
$14.34
Volume
629,050 shs
Average Volume
960,263 shs
Market Capitalization
$505.53 million
P/E Ratio
3.01
Dividend Yield
N/A
Price Target
$19.33

Voyager Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
107.7% Upside
$19.33 Price Target
Short Interest
Healthy
4.25% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.97
Upright™ Environmental Score
News Sentiment
0.63mentions of Voyager Therapeutics in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$27,272 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.64) to ($1.49) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.67 out of 5 stars

Medical Sector

74th out of 939 stocks

Biological Products, Except Diagnostic Industry

13th out of 158 stocks

VYGR stock logo

About Voyager Therapeutics Stock (NASDAQ:VYGR)

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

VYGR Stock Price History

VYGR Stock News Headlines

Bombshell 2024 election documentary
2024: America’s Last Election New documentary reveals why this could be America’s Last Election… and how the elites’ plan threatens to reset the entire U.S. economy, along with your 401(k), bank, and stock portfolio.
Knights fair well in 2-0 loss to Voyager
Voyager Therapeutics (NASDAQ: VYGR)
Bombshell 2024 election documentary
2024: America’s Last Election New documentary reveals why this could be America’s Last Election… and how the elites’ plan threatens to reset the entire U.S. economy, along with your 401(k), bank, and stock portfolio.
Voyager Therapeutics (NASDAQ:VYGR) Now Covered by HC Wainwright
Voyager 1 Sputters Back to Life
See More Headlines
Receive VYGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/29/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:VYGR
Fax
N/A
Employees
162
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$19.33
High Stock Price Target
$30.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+107.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$132.33 million
Pretax Margin
53.49%

Debt

Sales & Book Value

Annual Sales
$250.01 million
Cash Flow
$2.95 per share
Book Value
$5.37 per share

Miscellaneous

Free Float
51,749,000
Market Cap
$505.53 million
Optionable
Optionable
Beta
0.96
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Alfred W. Sandrock Jr. (Age 66)
    M.D., Ph.D., President, CEO & Director
    Comp: $825.41k
  • Mr. Peter P. Pfreundschuh CPA (Age 55)
    Chief Financial Officer
    Comp: $172.73k
  • Dr. Guangping Gao Ph.D.
    Founder & Member of Scientific Advisory Board
  • Dr. Mark A. Kay M.D. (Age 65)
    Ph.D., Founder
  • Dr. Phillip D. Zamore Ph.D.
    Founder & Member of Scientific Advisory Board
  • Ms. Robin Swartz (Age 52)
    COO & Acting Chief Business Officer
  • Mr. Todd Carter Ph.D. (Age 54)
    Chief Scientific Officer
  • Ms. Jacquelyn Fahey Sandell Esq.
    J.D., Chief Legal Officer
  • Ms. Michelle Quinn Smith
    Chief Human Resources Officer
  • Mr. G. Andre Turenne (Age 50)
    Advisor
    Comp: $600.3k

VYGR Stock Analysis - Frequently Asked Questions

Should I buy or sell Voyager Therapeutics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VYGR shares.
View VYGR analyst ratings
or view top-rated stocks.

What is Voyager Therapeutics' stock price target for 2024?

7 brokers have issued 1 year price objectives for Voyager Therapeutics' shares. Their VYGR share price targets range from $14.00 to $30.00. On average, they expect the company's share price to reach $19.33 in the next twelve months. This suggests a possible upside of 107.7% from the stock's current price.
View analysts price targets for VYGR
or view top-rated stocks among Wall Street analysts.

How have VYGR shares performed in 2024?

Voyager Therapeutics' stock was trading at $8.44 at the beginning of the year. Since then, VYGR stock has increased by 10.3% and is now trading at $9.31.
View the best growth stocks for 2024 here
.

When is Voyager Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our VYGR earnings forecast
.

How were Voyager Therapeutics' earnings last quarter?

Voyager Therapeutics, Inc. (NASDAQ:VYGR) posted its earnings results on Wednesday, February, 28th. The company reported $1.25 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $1.84. The firm had revenue of $90.06 million for the quarter, compared to analyst estimates of $4.95 million. Voyager Therapeutics had a trailing twelve-month return on equity of 63.89% and a net margin of 52.93%.

What ETF holds Voyager Therapeutics' stock?

iShares Neuroscience and Healthcare ETF holds 4,243 shares of VYGR stock, representing 0.82% of its portfolio.

What other stocks do shareholders of Voyager Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include Micron Technology (MU), REGENXBIO (RGNX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Amarin (AMRN), CRISPR Therapeutics (CRSP), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO) and Editas Medicine (EDIT).

Who are Voyager Therapeutics' major shareholders?

Voyager Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (9.63%), Vanguard Group Inc. (5.75%), Vanguard Group Inc. (4.66%), Price T Rowe Associates Inc. MD (2.28%), Price T Rowe Associates Inc. MD (2.28%) and Dimensional Fund Advisors LP (2.12%). Insiders that own company stock include Alfred Sandrock, Ecor1 Capital, Llc, Glenn Pierce, Julie Burek, Neurocrine Biosciences Inc, Omar Khwaja, Peter P Pfreundschuh, Robert W Hesslein, Robin Swartz, Rock Ventures Iii LP Third and Todd Alfred Carter.
View institutional ownership trends
.

How do I buy shares of Voyager Therapeutics?

Shares of VYGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VYGR) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners